mAb Program &
Process Development
End-to-end CMC consulting for monoclonal antibody programs, from cell line design and upstream optimization through downstream purification,
formulation, and BLA-ready process documentation.
CHO, NS0 and transient expression systems Expression and Platform Strategy
Expression Systems
CHO-K1 and CHO-S
NS0 Systems
Transient HEK293
Stable Pool Generation
Upstream Operations
Clone Selection
Media Optimization
Fed-Batch Development
Bioreactor Scale-Up
Downstream Operations
Protein A Capture
CEX and AEX Polishing
HIC Step Design
Viral Clearance
UF/DF and Formulation
mAb Process Development From Cell Line Development to Commercial Manufacturing Readiness
DES Pharma supports monoclonal antibody programs from early cell line and process design through late-stage manufacturing readiness. Our teams work across common mAb formats and expression approaches, including CHO-based commercial platforms, NS0-derived systems where relevant, and transient expression models used to accelerate early development. We help sponsors translate product quality goals into practical manufacturing strategies that support consistency, scale, and regulatory readiness.
Our process development support covers upstream and downstream operations as one connected program. That includes clone and cell line selection, media and feed optimization, bioreactor parameter development, harvest strategy, Protein A capture, polishing chromatography, viral clearance design, and formulation planning. We also help teams identify critical quality attributes and link process decisions to product quality, so development work supports later analytical control, comparability, and lifecycle management.
As programs move toward clinical manufacturing and commercialization, we support scale-up, tech transfer, process characterization, and process validation planning with a focus on phase-appropriate CMC decisions. The goal is to build an mAb process that is technically sound, transferable, and ready to support IND, pivotal, and BLA-stage expectations.
DES Pharma provides consulting across every unit operation
from upstream cell culture through formulation.The mAb Manufacturing Process Train
Cell Line Development
Clone selection and seed bank
Upstream Process
Media, feeds and bioreactor
Harvest and Clarification
Centrifuge and depth filtration
Protein A Capture
Affinity chromatography
Polishing
CEX / AEX / HIC steps
Viral Clearance
Nanofiltration & low pH
UF/DF & Formulation
DS concentration & buffer
Fill-Finish Interface
DP strategy & hold times
Phase-Appropriate Services
mAb Process Development by
Development Stage
Our service model adapts to your program’s stage
ensuring the right level of rigor, documentation, and investment at each milestone.
Building the mAb Process Foundation
Expression system selection, cell line development, and IND-enabling upstream and downstream process definition.
- Expression system selection across CHO, NS0, and transient platforms based on product profile and development goals
- Cell line development, clone screening, and early manufacturability assessment
- Upstream process development including media selection, feed strategy, and bioreactor parameter optimization
- Downstream purification design using Protein A capture and polishing steps such as ion exchange and hydrophobic interaction chromatography
- Early viral safety and clearance strategy aligned with cell substrate and process design
- Critical quality attribute identification and linkage to process development priorities
- Formulation screening for early stability, concentration range, and handling performance
- IND-enabling process and product characterization support
Optimizing for Clinical Manufacturing and Scale
Process refinement, GMP manufacturing support, tech transfer, and phase-appropriate CMC documentation.
- Clinical-stage upstream optimization for yield, consistency, and scalable control
- Refinement of harvest, clarification, capture, polishing, and UF/DF strategies for GMP manufacturing
- In-process control strategy development tied to product quality and process performance
- Process characterization studies to support parameter ranges and development-stage comparability
- Tech transfer support for upstream, downstream, and drug substance manufacturing workflows
- Phase-appropriate formulation and hold-time strategy for drug substance and drug product interfaces
- Manufacturing support for toxicology lots, engineering runs, and Phase 1/2 clinical supply
- CMC documentation support for IND updates and development-stage regulatory interactions
Commercial Process Readiness and BLA Preparation
Late-stage process characterization, PPQ planning, comparability strategy, and BLA-ready CMC documentation.
- Late-stage process characterization to define a robust commercial control strategy
- Scale-up support across equipment changes, site transfers, and campaign planning
- Comparability assessment planning for manufacturing, scale, raw material, or site changes per ICH Q5E
- PPQ preparation support for upstream and downstream operations
- Continued refinement of viral clearance, impurity clearance, and resin lifetime strategy
- Commercial formulation and process interface planning for fill-finish readiness
- Lifecycle planning for process validation, continued process verification, and post-approval changes
- BLA-ready process narratives and supporting CMC documentation development
mAb Process Expertise Deep Technical Capability Across the mAb Manufacturing Platform
Our process development consultants have hands-on experience with CHO-based commercial platforms, protein A purification design, polishing strategy, viral clearance qualification, and formulation development for concentration-sensitive mAb drug substances. We understand how process decisions at each stage propagate forward into CQA control, comparability, and regulatory expectations, and we bring that integrated perspective to every engagement.
We work alongside in-house process development scientists, technical operations teams, and CDMO partners, providing technical oversight, authoring study protocols and characterization reports, and ensuring that process knowledge is captured in a form that supports BLA-stage documentation and lifecycle management.
Cell Line and Expression Strategy
CHO host selection and adaptation, stable transfection and pool generation, clone screening and selection criteria, seed bank establishment, and early culture performance assessment including growth, productivity, and product quality.
Upstream Bioprocess Development
Media and feed strategy development, dissolved oxygen and pH control, temperature shift optimization, culture duration, fed-batch and perfusion process design, and bioreactor scale-up from bench to 2,000L+ scale.
Downstream Purification Design
Protein A affinity capture optimization including load density and wash strategies, polishing chromatography design (CEX, AEX, HIC), nanofiltration for viral reduction, and UF/DF concentration and diafiltration development.
Viral Safety & Clearance
Viral clearance study design and vendor management, orthogonal clearance step selection (low pH inactivation, nanofiltration, chromatographic removal), clearance factor summation, and regulatory documentation aligned with ICH Q5A and PDA TR47.
Formulation & Drug Substance Interface
Excipient screening and compatibility, pH and ionic strength optimization for aggregation and stability, high-concentration formulation for subcutaneous applications, and DS / DP interface hold-time and shipping stress studies.
Why DES Pharma
What We Bring to Your mAb
Process Program
Practical expertise, regulatory alignment, and CDMO-side experience,
applied to programs at every stage of the development lifecycle.
Upstream and Downstream Integration
We develop upstream and downstream as a connected program, ensuring that decisions in cell culture, glycan profiles, HCP levels, aggregation, are visible in purification design and CQA control strategy.
Phase-Calibrated Rigor
We apply the right level of characterization and documentation discipline for your stage, preventing over-investment early and ensuring sufficient process understanding exists before entering pivotal and commercial phases.
CQA-Linked Process Thinking
Every process decision is connected to its downstream impact on product quality attributes. We help teams build a mechanistic understanding that will support both regulatory review and lifecycle change management.
CDMO Technical Oversight
We know how CDMOs operate and where technical gaps emerge. We provide on-site or remote oversight for technology transfer, engineering runs, and GMP manufacturing campaigns across leading contract manufacturers.
Regulatory-Ready Documentation
Process development work is documented in formats that translate directly into IND CMC sections, BLA Module 3.2.S narratives, and PPQ protocols, reducing the gap between development and filing deliverables.
Lifecycle and Change Management
We design processes with post-approval flexibility in mind. Comparability frameworks, resin lifetime strategies, and raw material qualification approaches are built into the development program from the start.
Our Engagement Model
How We Work on mAb
Process Programs
We integrate directly into your development team, whether you need a single expert to lead a specific workstream or a broader team to accelerate an entire CMC program. Engagements are structured around deliverables and milestones, not time-and-materials ambiguity.
Program Review and Gap Assessment
We review your existing process data, development history, and regulatory context to identify gaps relative to phase-appropriate expectations and your target CMC pathway.
Development Strategy and Work Plan
We define a prioritized process development roadmap covering key studies, decision points, timeline, and resourcing, integrated with your analytical and regulatory plans.
Technical Execution and Oversight
Our consultants lead or support study execution, directing CDMO activities, reviewing experimental data, interpreting results, and maintaining scientific rigor throughout development.
CMC Documentation and Regulatory Filing
Development reports, IND sections, and BLA Module 3 narratives are authored concurrently with the technical work, ensuring the filing package reflects the actual process understanding achieved.
Regulatory Framework
ICH Q11
ICH Q8(R2)
ICH Q5A
ICH Q5E
ICH Q6B
FDA Guidance
Get Started Build a Technically Sound, Transfer-Ready mAb Process
Whether you’re designing your first CHO process or preparing for PPQ and BLA submission, our consultants are ready to assess where your program stands and define the right path forward.